It stopped making the Band-Aid. What is left is a $94-billion bet that the future of Johnson & Johnson is written on a prescription pad and a robotic arm.
For most of the last century, if you opened a bathroom cabinet in America you were looking at Johnson & Johnson. The baby shampoo, the Listerine, the bottle of Tylenol, the box of Band-Aids with the little metal tin. That was the company most people thought they knew. In 2023, J&J packed almost all of it into a box, labeled it Kenvue, and sent it off to live as its own public company.
What is left is a different animal. The Johnson & Johnson of 2026 does not want to be in your medicine cabinet. It wants to be in the operating room, the oncology ward and the cardiac cath lab. Two businesses now carry the entire 139-year-old name: Innovative Medicine, which makes prescription drugs, and MedTech, which makes the machines and implants that surgeons use. In 2025 those two segments together produced $94.2 billion in sales.
Strip away the history and J&J is two companies wearing one script logo. The larger half, Innovative Medicine, develops patent-protected prescription drugs across oncology, immunology, neuroscience, cardiovascular disease and pulmonary hypertension. It reported roughly $60.4 billion in 2025 sales. The smaller half, MedTech, makes surgical tools, heart pumps, ablation catheters and vision products, and reported about $33.8 billion.
The way to understand the portfolio is not by counting products but by counting platforms. J&J talks about roughly eleven "priority platforms," each generating more than a billion dollars a year on its own. The clearest example is Darzalex, an antibody therapy for multiple myeloma, which crossed $3 billion in sales in a single quarter of 2025. Alongside it sit immunology drugs like Stelara and Tremfya and a cell therapy, Carvykti, developed with Legend Biotech that reprograms a patient's own immune cells to attack cancer.
J&J no longer sells to shoppers. Its customers are hospitals, surgeons, oncologists, health systems, insurers and government payers across roughly 175 countries. A device customer might be a cardiologist who installs a Shockwave lithotripsy system and then buys its single-use catheters for years afterward. A medicine customer might be a national health service negotiating the price of a myeloma drug. The patient is the end user, but the buyer is almost always an institution.
The company's founding problem was infection. In 1885, three brothers - Robert Wood, James Wood and Edward Mead Johnson - heard the antiseptic pioneer Joseph Lister argue that invisible germs on the operating table were killing patients. A year later they started a company in New Brunswick, New Jersey, to make ready-to-use sterile surgical dressings. It opened with 14 employees, eight women and six men. By 1888 it was selling the first mass-produced first-aid kits, originally designed for railroad workers stranded far from a doctor.
The problems have grown more complex since - multiple myeloma, calcified arteries, immune disease, cancers that resist chemotherapy - but the shape is the same: identify a hard clinical problem, then engineer a product a professional can use. What changed is the difficulty of the engineering. A sterile bandage is a solved problem. A cell therapy that removes a patient's T-cells, reprograms them and puts them back to hunt cancer is not, and the cost of getting it right - trials, factories, regulators on three continents - is exactly the barrier that keeps most companies out of the room where J&J operates.
Most large healthcare firms pick a lane. Pfizer, Merck, AbbVie and Bristol Myers Squibb are drug companies. Medtronic, Stryker, Boston Scientific and Intuitive Surgical are device companies. J&J is unusual in running both at full scale under one roof, which lets it move capital between a booming drug franchise and a device pipeline without leaving its own walls. The trade-off is complexity: two very different businesses, two regulatory rhythms, two sales forces. The company's answer to that complexity has been to keep simplifying - first by shedding consumer health, now by preparing to spin off its DePuy Synthes orthopedics unit.
On the medicine side, the names that matter are mostly ones patients never ask for by brand. Darzalex and Carvykti fight multiple myeloma. Stelara and Tremfya treat immune-driven diseases like psoriasis and Crohn's. Others target neuroscience, cardiovascular disease and pulmonary hypertension. These are not products you pick off a shelf - a physician prescribes them, a payer approves them, and a specialty pharmacy or hospital delivers them.
On the device side, the catalog reads like a hospital requisition form. Electrophysiology catheters that map and ablate irregular heartbeats. The Shockwave system that cracks calcium inside a clogged artery with sound waves. Abiomed's Impella, a pump small enough to thread into the heart and keep blood moving during a high-risk procedure. Vision products for cataract and refractive surgery. And, in development, Ottava - the surgical robot J&J is betting will give it a foothold in soft-tissue procedures. Where the medicines are consumed once and prescribed again, many of the devices are installed once and then feed on a steady diet of single-use parts.
Innovative Medicine runs on patents. A drug that clears trials and regulators earns years of protected pricing before generics or biosimilars arrive, so the game is a constantly refilling pipeline - launch the next blockbuster before the last one loses exclusivity. MedTech runs closer to razor-and-blade economics: sell a surgeon a system, then sell the disposables that system consumes. Underneath both, J&J buys growth when it cannot build it fast enough, folding in companies like Abiomed, which makes the Impella heart pump, and Shockwave. Cash left over funds a dividend the company has raised for more than 60 consecutive years.
The one-page document that runs the placeThe deepest expertise J&J owns is the boring, expensive middle of healthcare: running large clinical trials, navigating regulators, manufacturing biologics and sterile devices at global scale, and selling to institutions. That is the moat. In the market it sits among the largest healthcare companies on earth - big enough to have held a top-tier credit rating, defensive enough that investors treat it as a place to hide during downturns. The open question analysts keep asking is whether, post-Kenvue, it now leans too heavily on pharmaceutical revenue.
The next two years will answer part of that. J&J is pushing toward an FDA submission for Ottava, a soft-tissue surgical robot meant to compete in an operating-room category Intuitive Surgical has largely owned. At the same time it plans to separate DePuy Synthes - a move one executive framed bluntly as "shrinking to grow faster." For a company that spent a century adding, the current instinct is to subtract.
Size has costs, too. J&J has spent years managing litigation tied to talc-based products it once sold, working through the courts and settlement structures - a reminder that a 139-year-old consumer legacy does not vanish the moment the brands are spun off. Management's broader response has been the one running through this whole story: narrow the company to what it does best, medicine and machines, and let the parts that no longer fit find their own owners. In 2025 that discipline showed up in the numbers, with sales climbing about 6% to $94.2 billion and adjusted earnings near $10.79 a share.
Which is the strange thing about the new Johnson & Johnson. The name is the most familiar in healthcare, printed in the same red script it has used since the 1880s. But the company behind it has quietly become something the average shopper will never touch directly - a maker of the medicines and machines that show up only when things get serious.